Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Leukocyte Disorder Clear all
Withdrawn Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5 Percent or More of Peripheral Blood White Cells, CD22 Positive, Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells, Lymphoblasts 20 Percent or More of Peripheral Blood White Cells, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Interventions
Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced May 21, 2026, 7:19 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
Interventions
data collection
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced May 21, 2026, 7:19 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Chronic Granulomatous Disease (CGD)
Interventions
Not listed
Lead sponsor
Ensoma
Industry
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Montelukast/ Singulair, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Neutropenia
Interventions
SPI-2012, Pegfilgrastim, Docetaxel, Cyclophosphamide
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Glendale, Arizona • Scottsdale, Arizona • Fresno, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced May 21, 2026, 7:19 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
5 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
Interventions
Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 25 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Reslizumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
66
States / cities
Birmingham, Alabama • Homewood, Alabama • Jasper, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2016 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Leukemia, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases
Interventions
Allogeneic bone marrow transplantation, Peripheral blood stem cell transplantation
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 66 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Neutropenia (Low White Blood Cell Count)
Interventions
Filgrastim Hospira (US), U.S.-approved Neupogen®
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Candidiasis, Chronic Mucocutaneous
Interventions
Amphotericin B
Drug
Lead sponsor
Matinas BioPharma Nanotechnologies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced May 21, 2026, 7:19 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Plasma and urine metabolomics
Diagnostic Test
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
2 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced May 21, 2026, 7:19 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
Vonsetamig
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 21, 2026, 7:19 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Prevention of Chemotherapy-induced Myelosuppression
Interventions
ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
Drug
Lead sponsor
Aileron Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Tamarac, Florida • Huntersville, North Carolina • Wilson, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced May 21, 2026, 7:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Observed eating session
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced May 21, 2026, 7:19 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced May 21, 2026, 7:19 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Food Hypersensitivity, Anaphylaxis, Eosinophilic Esophagitis, Food Sensitivity, Food Intolerance, Food Allergy in Infants
Interventions
Not listed
Lead sponsor
Food Allergy Research & Education
Other
Eligibility
Not listed
Enrollment
23,000 participants
Timeline
2017 – 2027
U.S. locations
1
States / cities
McLean, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Neutropenia
Interventions
Mavorixafor
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
St. Petersburg, Florida • Iowa City, Iowa • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Leukemia
Interventions
White Blood Cell Transfusion
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced May 21, 2026, 7:19 PM EDT
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Eosinophilic Esophagitis, EoE
Interventions
Cytosponge™ Cell Collection Device
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Rochester, Minnesota • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Eosinophilic Esophagitis, Milk Allergy
Interventions
Viaskin Milk 500 mcg, Viaskin Placebo
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis
Interventions
AK002
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Ventura, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced May 21, 2026, 7:19 PM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
IFN-Gamma Therapy, CGD Gene Mutation, CGD Response to IFNg, CGD - Chronic Granulomatous Disease, Immunodeficiency Disease
Interventions
IFN-gamma
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced May 21, 2026, 7:19 PM EDT
Not listed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions
benralizumab, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced May 21, 2026, 7:19 PM EDT